

ForPatients

by Roche

Wet Age-Related Macular Degeneration

A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD

Trial Status

Not Yet Recruiting

Trial Runs In

0 Countries

Trial Identifier

NCT06847542 2024-516924-32-00
MR45625

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

The purpose of this study is to evaluate the effectiveness, safety, and PROs of the port delivery system with ranibizumab 100 milligrams/milliliters (mg/mL) refilled every 36 weeks (Q36W) in participants with nAMD.

Hoffmann-La Roche

Sponsor

Phase 3

Phase

NCT06847542 2024-516924-32-00 MR45625

Trial Identifiers

Eligibility Criteria:

Gender

All

Age

>=50 Years

Healthy Volunteers

No
